CIENCIASMEDICASNEWS: 2025

martes, 23 de diciembre de 2025

What impact does melatonin have on sleep cycle? (Medscape AI)

Melatonin is an endogenous hormone that plays a central role in the timing and quality of sleep by acting on the body’s circadian system and facilitating sleep onset and maintenance. https://www.medscape.com/ai-search?query=What%20impact%20does%20melatonin%20have%20on%20sleep%20cycle%3F&ecd=wnl_tp10_daily_251217_MSCPEDIT_etid7962970&uac=148436CN&impID=7962970

Holiday Heart Syndrome: Which seasonal habits most often trigger atrial fibrillation (Medscape AI)

https://www.medscape.com/ai-search?query=Holiday%20Heart%20Syndrome:%20Which%20seasonal%20habits%20most%20often%20trigger%20atrial%20fibrillation&ecd=wnl_tp10_daily_251220_MSCPEDIT_etid7972120&uac=148436CN&impID=7972120 Holiday Heart Syndrome (HHS) is most commonly precipitated by behavioral changes during holiday periods that promote atrial fibrillation (AF). Key seasonal habits include:

CRC: How Ultraprocessed Foods and Sugary Drinks Impact Risk David A. Johnson, MD

https://www.medscape.com/viewarticle/crc-how-ultraprocessed-foods-and-sugary-drinks-impact-risk-2025a1000zq6?ecd=wnl_edit_tpal_etid7973201&uac=148436CN&impID=7973201

Colorectal cancer: experts discuss the clinical guidelines +... +... +... +...

Neoadjuvant Chemotherapy in Colon Cancer: Who Is the Ideal Candidate? https://decisionpoint.medscape.com/oncology/viewarticle/944624?src=0_nl_sm_0&uac=148436CN Chiara Cremolini, MD, PhD, University of Pisa Appendiceal Cancers: How Are They Different From Colon Cancer? https://decisionpoint.medscape.com/oncology/viewarticle/921574?src=0_nl_sm_0&uac=148436CN Katrina S. Pedersen, MS, MD, Washington University Molecular Profiling for Early-onset Colorectal Cancer (CRC) https://decisionpoint.medscape.com/oncology/viewarticle/930635?src=0_nl_sm_0&uac=148436CN John L. Marshall, MD, Georgetown University Treatment Options for Patients With MSI-H Locally Advanced Rectal Cancer https://decisionpoint.medscape.com/oncology/viewarticle/990258?src=0_nl_sm_0&uac=148436CN Katrina S. Pedersen, MS, MD, Washington University

Why are noncardiovascular deaths rising among patients with heart failure (Medscape AI) +...

https://www.medscape.com/ai-search?query=Why%20are%20noncardiovascular%20deaths%20rising%20among%20patients%20with%20heart%20failure&ecd=wnl_tp10_daily_251221_MSCPEDIT_etid7968996&uac=148436CN&impID=7968996 Patients with heart failure are living longer after acute ischemic events, but now face a growing burden of systemic comorbidities that drive non-cardiovascular mortality.

What are the patterns of drug-induced liver injury with GLP-1 agonists? (Medscape AI) +... +++++ ++ +

Position-wise mutation analysis and temporal changes in SARS CoV-2 Envelope (E) protein variants Anwesa Saha [1,†] , Diganta Mukherjee [1,†] , Aparna Mukhopadhyay* [1]

https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8011 SARS CoV-2 is a positive-sense, single-stranded RNA virus. The genome of the virus undergoes numerous mutations, making the development of universally effective drugs challenging. Among its structural proteins, the Envelope (E) protein acts as an ion transporter and virulence factor, making it a potential therapeutic target. Based on the literature available to date, we have identified several functionally important sites in the E protein. These include residues involved in lysosomal deacidification; those of the FYXY motif, involved in amyloid formation in the host; and the PDZ-binding DLLV motif. We focus our analysis on the significance of these residues while also searching for other interesting mutational patterns. In this study, we conducted a comprehensive mutational analysis of the SARS CoV-2 E protein utilizing bioinformatics, statistics, and structural modeling tools. Over 1.4 million sequences were retrieved from the NCBI virus database, filtered, clustered, and aligned chronologically. By employing a combination of web-based tools and in-house Python scripts, we analyzed per-residue Shannon entropy, mutation types, evolutionary pressure, and predicted structural impact (via ∆∆G). We observed a significant number of residues under diversifying selection. This suggests that new amino acids are being sampled at various positions in the protein, providing functional or structural benefits to the virus. A cyclical pattern of mutation and reversion was observed at position 9, stabilizing at a particular mutation. Similar trends appeared at position 11. These mutations may be functionally relevant, which need to be explored in future. However, the key regions have remained conserved over time. The evolution of cognitive abilities in marine animals: a hypothesis based on insights about cognition gene polymorphisms in Coelocanths and lungfish Zhizhou Zhang* [1], Shuaiyu Zhang [2], Yongdong Xu* [2] https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8001 Both coelacanths and lungfish have fossil evidence dating back 400 million years, placing them at a critical evolutionary juncture when marine animals transitioned to terrestrial environments. An intriguing question lies in the extent to which their cognitive abilities had evolved before they crawled onto land. While no fossil DNA exist for extinct coelacanths or lungfish, studies on their extant species offer clues. Notably, the biological traits of coelacanths and lungfish have been remarkably stable over the past 70 million years, suggesting that some genomic regions in their genomic sequences possess exceptional stability. This raises the possibility of inferring their cognition gene polymorphism patterns (CGPPs) and evolutionary positioning through genomic analyses of modern samples. By employing 471 whole-genome sequence samples, including archaic humans (Neanderthals, Denisovans and more), modern humans, other vertebrates (fish, amphibians, reptiles, birds, rodents, mammals) plus four coelacanth and three lungfish samples, together with 18 human cognition-related genes and their total of 223 SNVs (Single-Nucleotide Variations),comparative analyses revealed that the CGPPs of both coelacanths and lungfish are evolutionarily closer to those of archaic humans than those of most other animal groups. The CGPP appears to occupy an evolutionary inflection point, bridging diverse animal lineages to archaic hominoids. Our observational results suggest a hypothesis (to be validated in the future) that the genetic architecture underlying human cognitionseemsto have beenestablished during the evolutionary stage of fish, predating the emergence of tetrapods.

Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection Authors: Joyce A. O’Shaughnessy, MD; Aditya Bardia, MD, MPH, FASCO

https://www.medscape.org/viewarticle/1003008?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1003008-cta

FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219083s000lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition Action The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Disease or Condition Symptomatic oHCM is an inherited condition where patients have thickened heart muscle and reduced blood flow from the left side of the heart to the rest of the body, causing symptoms such as shortness of breath, fatigue, and potentially life-threatening cardiac events. Myqorzo Effectiveness The effectiveness and safety of Myqorzo were studied in 282 adults with symptomatic oHCM randomly assigned to receive Myqorzo or placebo for 24 weeks. At the end of the study, participants receiving Myqorzo had an increase in exercise capacity measured by peak oxygen uptake compared to no change in exercise capacity among those receiving placebo. Also, 59 percent of participants receiving Myqorzo experienced an improvement in physical activity limitations (measured using the New York Heart Association Classification system) compared to 24 percent of individuals receiving placebo. Safety Information Myqorzo reduces contraction of the heart muscle which can cause heart failure. Because of the risk for heart failure, patients treated with Myqorzo must be monitored with echocardiograms, an imaging test that shows how well the heart is working. Because of the heart failure risk and need for monitoring, Myqorzo is only available through a restricted program called the Myqorzo Risk Evaluation and Mitigation Strategy (REMS). Patients must also avoid certain prescription medicines that interfere with the metabolism (breakdown) of Myqorzo. See the prescribing information for additional information on risks associated with Myqorzo. Designations Myqorzo received Orphan Drug Designation and Breakthrough Therapy Designation for this indication.

Update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV

https://clinicalinfo.hiv.gov/en/news/update-guidelines-prevention-and-treatment-opportunistic-infections-children-and-exposed-hiv-2 Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new

San Antonio Breast Cancer Symposium (SABCS) 2025 Conference News

https://www.medscape.com/viewcollection/37937

NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC Edited by Joyani Das

https://www.medscape.com/viewarticle/nice-endorses-chemo-free-first-line-option-egfr-nsclc-2025a1000zyy

Moderately Hypofractionated Definitive Radiotherapy Linked to Favourable Outcomes in Inoperable Non-Extremity Sarcomas Edited by Vineeta Teotia

https://www.medscape.com/viewarticle/moderately-hypofractionated-definitive-radiotherapy-linked-2025a1000zkv

Novel Treatment Combo Ups Survival in Multiple Myeloma Sharon Worcester December 22, 2025

https://www.medscape.com/viewarticle/novel-treatment-combo-ups-survival-multiple-myeloma-2025a1000zz9

Childhood Cancer Survivors Face Long-Term Meningioma Risk Edited by Gargi Mukherjee December 22, 2025

https://www.medscape.com/viewarticle/childhood-cancer-survivors-face-long-term-meningioma-risk-2025a1001026

FDA Approves Novel Fibrinogen Concentrate for CFD Sharon Worcester December 23, 2025

https://www.medscape.com/viewarticle/fda-approves-novel-fibrinogen-concentrate-cfd-2025a100103u

Sexual Dysfunction in Cancer: More Common Than You Think Caroline Guignot

https://www.medscape.com/viewarticle/sexual-dysfunction-cancer-more-common-than-you-think-2025a100102s

Tumor-Like Masses, Abdominal Swelling, Pancreatic Involvement: Making Sense of IgG4-Related Disease, a Multiorgan Fibroinflammatory Condition Authors: Emanuel Della Torre, MD, PhD; J. Matthias Löhr, MD, PhD; John H. Stone, MD, MPH

https://www.medscape.org/viewarticle/1002730?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1002730-cta

FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212320s019lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves First Prescription Oral Medicine for Iron Deficiency in Pediatric Patients Ages 10 and Older Action The U.S. Food and Drug Administration (FDA) approved Accrufer (ferric maltol) capsules to treat pediatric patients ages 10 and older with iron deficiency. Accrufer was initially approved in 2019 for adults with iron deficiency. Disease or Condition Iron deficiency is the most common cause of anemia and occurs if there is not enough iron in the blood. Without enough iron, the body cannot make sufficient hemoglobin, a protein inside red blood cells that carries oxygen throughout the body. Iron deficiency anemia can result in symptoms such as fatigue, pale skin, and dizziness. Causes can include blood loss from gastrointestinal conditions, menstruation, food malabsorption, and insufficient iron in the diet. Data Supporting Accrufer The efficacy of Accrufer to treat iron deficiency in pediatric patients ages 10-17 was assessed in the FORTIS trial (NCT05126901). The trial treated 24 patients with age-based dosing of Accrufer twice daily, and showed a clinically meaningful average increase in hemoglobin of 1.1 g/dL at Week 12. This, on average, would be the expected increase in hemoglobin with one blood transfusion. Safety Information Patients should not take Accrufer if they are allergic to Accrufer or any of its excipients, have hemochromatosis and other iron overload syndromes, or receive repeated blood transfusions. In addition, patients should avoid Accrufer if they are experiencing an inflammatory bowel disease flare and should be aware of the risks of iron overload. The most common side effects of Accrufer are flatulence, diarrhea, constipation, discolored feces, abdominal pain, nausea, vomiting, and abdominal discomfort/distension.

Advanced Neuroendocrine Tumors: Integrating Emerging Targeted Therapies Into Patient Care Authors: Marianne Pavel, MD; Jaume Capdevila, MD, PhD; Rachel Riechelmann, MD, PhD; Simron Singh, MD, MPH, FRCPC

https://www.medscape.org/viewarticle/1002665?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251223-OUS-HONC-1002665-cta

lunes, 22 de diciembre de 2025

E-cigarette use is linked to higher heart attack risk, especially in former smokers

https://www.news-medical.net/news/20251214/E-cigarette-use-is-linked-to-higher-heart-attack-risk-especially-in-former-smokers.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=cardiology_newsletter_17_december_2025 A large meta-analysis suggests that vaping is not cardiovascularly neutral, with elevated heart attack risk concentrated among people who previously smoked, raising questions about e-cigarettes as harm-reduction tools.

Genes influence the gut microbiome beyond the individual

https://www.news-medical.net/news/20251219/Genes-influence-the-gut-microbiome-beyond-the-individual.aspx

Skin and internal organs sense cold through different molecular pathways

https://www.news-medical.net/news/20251219/Skin-and-internal-organs-sense-cold-through-different-molecular-pathways.aspx

Simple fruit granola intervention shows promising cardio-renal signals in CKD patients

https://www.news-medical.net/news/20251221/Simple-fruit-granola-intervention-shows-promising-cardio-renal-signals-in-CKD-patients.aspx A small Japanese study suggests that a low-salt, oat-based granola breakfast may improve blood pressure, lipid risk markers, and gut health indicators in people with moderate chronic kidney disease, while highlighting the need for larger controlled trials.

Study charts the escalating spread of resistant bacteria and fungi

https://www.news-medical.net/news/20251222/Study-charts-the-escalating-spread-of-resistant-bacteria-and-fungi.aspx

Cytokinetics heart drug wins FDA approval, the biotech’s first The clearance of Myqorzo ends one of the longest industry’s R&D droughts in the industry

https://www.statnews.com/2025/12/19/cytokinetics-heart-drug-myqorzo-fda-approval/ By Adam FeuersteinDec. 19, 2025 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Study revives debate about unpopular diet for cancer patients Neutropenic diet led to fewer infections in those with blood cancer By Angus ChenDec. 22, 2025 Cancer Reporter

https://www.statnews.com/2025/12/22/cancer-neutropenic-diet-lessened-risk-of-infection/ By Angus ChenDec. 22, 2025 Cancer Reporter

What Ozempic might tell us about the future of Alzheimer’s The GLP-1 might not treat Alzheimer’s, but it still offers lessons

https://www.statnews.com/2025/12/22/ozempic-alzheimers-iconic-drugs/ By Jason KarlawishDec. 22, 2025 Karlawish is a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, co-director of the Penn Memory Center, and executive producer of the “Age of Aging” podcast.

NIH study was a beacon for the topical steroid withdrawal community. Then, amid federal upheaval, the research stalled By Eric BoodmanDec. 22, 2025

NIH study was a beacon for the topical steroid withdrawal community. Then, amid federal upheaval, the research stalled Purchasing freeze and layoffs sidelined effort to help patients with a painful skin condition By Eric BoodmanDec. 22, 2025 https://www.statnews.com/2025/12/22/topical-steroid-withdrawal-study-derailed-american-science-shattered/

Advancing Precision Oncology: Recent Progress and Future Outlook Authors: Vivek Subbiah, MD; Elena Garralda, MD, MSc; Fernando Lopez-Rios, MD, PhD

https://www.medscape.org/viewarticle/advancing-precision-oncology-recent-progress-and-future-2025a1000a6b?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-advancing-precision-oncology-recent-progress-and-future-2025a1000a6b-cta

A 36-Year-Old Woman With Epigastric Pain, Dysphagia, Vomiting, and New Skin Changes Sarah El-Nakeep, MD December 11, 2025 (Case Challenge)

https://reference.medscape.com/viewarticle/36-year-old-woman-epigastric-pain-dysphagia-vomiting-and-new-2025a1000xx5?ecd=WNL_casechlg_251221_MSCPREF_etid7969200&uac=148436CN&impID=7969200 A 36-Year-Old Woman With Epigastric Pain, Dysphagia, Vomiting, and New Skin Changes A 36-year-old woman presents with a 1-month history of epigastric abdominal pain associated with several episodes of postprandial vomiting and a yearlong history of progressive dysphagia requiring liquids to facilitate swallowing. What's the diagnosis?

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-1002681-cta

Long COVID in Context: A Closer Look at Post-Viral Syndrome and Management Approaches Authors: Ziyad Al-Aly, MD; Bin Cao, MD

https://www.medscape.org/viewarticle/1002795?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-1002795-cta

Highlights From Milan 2025: Bispecific Antibodies in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Authors: Chan Cheah, MBBS, DMSc; Matthew Lunning, DO, FACP

https://www.medscape.org/viewarticle/1002726?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251222-OUS-HONC-1002726-cta

FDA Approves Drug to Treat Chronic, Progressive Lung Disease

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220449s000lbl.pdf?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Treat Chronic, Progressive Lung Disease Action The U.S. Food and Drug Administration (FDA) approved Jascayd (nerandomilast) tablets to treat adults with progressive pulmonary fibrosis (PPF). Jascayd was previously approved to treat idiopathic pulmonary fibrosis (IFP) in adults. Disease or Condition PPF is a chronic disease characterized by gradual, irreversible scarring of the lungs, which can lead to progressive breathing difficulties. PPF is an umbrella term that can describe progressive lung scarring in many interstitial lung diseases. Data Supporting Jascayd Jascayd’s efficacy for PPF was demonstrated in FIBRONEER-ILD (NCT05321082), a randomized, double-blind, placebo-controlled study that enrolled 1,178 adults with PPF. Participants were randomly assigned 1:1:1 to receive twice daily administration of Jascayd 9 mg, Jascayd 18 mg, or placebo for at least 52 weeks. Patients treated with either dose of Jascayd showed significantly slower rates of lung function decline compared to placebo, based on the primary endpoint of absolute change in forced vital capacity (FVC) — the maximum amount of air a person can forcefully exhale after taking the deepest possible breath — at 52 weeks. The adjusted, average decline in patients receiving 18 mg or 9 mg Jascayd was -72 mL and -85 mL, respectively, whereas the placebo group had a -151 mL decline. Additionally, patients receiving Jascayd had fewer events of either interstitial lung disease exacerbations, respiratory hospitalizations, or death over the course of the trial. The recommended dosages for Jascayd are 9 mg or 18 mg orally twice a day, approximately 12 hours apart. Safety Information The safety of Jascayd in patients with PPF was generally consistent with that observed in patients with IFP, a previously approved indication. Side effects include diarrhea, decreased weight, decreased appetite, and nausea. See the prescribing information for more safety information. Designation Jascayd received a Breakthrough Therapy Designation for the PPF indication.

Primary Care 5 - Guideline Updates: Management of Acne in Primary Care Dr Catherine Fernando; Dr Kevin Fernando

Acne Management of Acne in Primary Care Dr Catherine Fernando; Dr Kevin Fernando Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for healthcare professionals and ultimately help improve patients' lives. •Lifestyle factors to advise https://reference.medscape.com/cc3/p10/management-acne-primary-care-2024a1000bnf?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Gradual use of topical retinoids https://reference.medscape.com/cc3/p10/management-acne-primary-care-2024a1000bnf?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Treating acne in skin of color https://reference.medscape.com/cc3/p10/management-acne-primary-care-2024a1000bnf?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1

Primary Care 4 - Guideline Updates: Lifestyle Changes for Managing Hypertension Dr Kevin Fernando

Hypertension Lifestyle Changes for Managing Hypertension Dr Kevin Fernando Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •Alcohol limits for BP control https://reference.medscape.com/cc3/p10/lifestyle-changes-managing-hypertension-2023a10009o5?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998 •Impact of the DASH diet https://reference.medscape.com/cc3/p10/lifestyle-changes-managing-hypertension-2023a10009o5?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998 •Best interventions to reduce CV events https://reference.medscape.com/cc3/p10/lifestyle-changes-managing-hypertension-2023a10009o5?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998 RELATED ARTICLES •What Do Physicians Need to Know About Weight-loss Medications? What Do Primary Care Practitioners Need to Know About Weight-loss Medications? Dr Pam Brown offers practical information for general practitioners on the safe prescribing of liraglutide, semaglutide, and tirzepatide for weight loss Dr Pam Brown https://reference.medscape.com/cc1/p10/what-do-primary-care-practitioners-need-know-about-weight-2025a10006lb?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998 •Managing Lipids With Inclisiran: The Role of Community Pharmacists Managing Lipids With Inclisiran: The Role of Community Pharmacists Sachin Tammewar discusses the secondary prevention of cardiovascular disease in general practice, with reference to a case study on a pharmacist-led lipid clinic Sachin Tammewar https://reference.medscape.com/cc1/p10/managing-lipids-inclisiran-role-pharmacists-primary-care-2025a1000f6l?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998

Primary Care 3 - Guideline Updates: Identifying People at High Risk of Type 2 Diabetes Dr Kevin Fernando; Dr Eimear Darcy

Prediabetes Identifying People at High Risk of Type 2 Diabetes Dr Kevin Fernando; Dr Eimear Darcy Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •Defining prediabetes cutoffs https://reference.medscape.com/cc3/p10/pchack-prediabetes-2023a1000ldy?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#14 •BMI and HbA1c testing https://reference.medscape.com/cc3/p10/pchack-prediabetes-2023a1000ldy?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#14 •When to start metformin https://reference.medscape.com/cc3/p10/pchack-prediabetes-2023a1000ldy?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#14

Primary Care 2 - Guideline Updates: Iron Studies // Lipid Management // Raised Platelet Counts

Iron Studies Interpreting Iron Studies in Primary Care Dr Kevin Fernando Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •Checking serum ferritin https://reference.medscape.com/cc3/p10/interpreting-iron-studies-primary-care-2023a10002ty?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#11 •Best investigation for IDA https://reference.medscape.com/cc3/p10/interpreting-iron-studies-primary-care-2023a10002ty?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#11 •Interpreting low serum iron https://reference.medscape.com/cc3/p10/interpreting-iron-studies-primary-care-2023a10002ty?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#11 Lipid Management Lipid Management for the Primary and Secondary Prevention of Cardiovascular Disease Niraj Lakhani; Dr Kevin Fernando Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •The role of lifestyle changes https://reference.medscape.com/cc3/p10/lipid-management-primary-and-secondary-prevention-2025a10000kr?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Beyond QRISK3: lifetime CV risk https://reference.medscape.com/cc3/p10/lipid-management-primary-and-secondary-prevention-2025a10000kr?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Managing raised triglycerides https://reference.medscape.com/cc3/p10/lipid-management-primary-and-secondary-prevention-2025a10000kr?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 Raised Platelet Counts Managing Raised Platelet Counts and Their Cancer Risk in Primary Care Dr Kevin Fernando Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •When to investigate thrombocytosis https://reference.medscape.com/cc3/p10/managing-raised-platelet-counts-and-their-cancer-risk-2024a10008nq?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#8 •Cancer risk with high platelets https://reference.medscape.com/cc3/p10/managing-raised-platelet-counts-and-their-cancer-risk-2024a10008nq?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#8 •Actions for high platelet counts https://reference.medscape.com/cc3/p10/managing-raised-platelet-counts-and-their-cancer-risk-2024a10008nq?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#8

Primary Care 1 - Guideline Updates: Use of Liraglutide, Semaglutide, and Tirzepatide for Adults Living With Overweight and Obesity Dr Kevin Fernando; Dr Eimear Darcy

Obesity Use of Liraglutide, Semaglutide, and Tirzepatide for Adults Living With Overweight and Obesity Dr Kevin Fernando; Dr Eimear Darcy Medscape presents Primary Care Hacks, a series of clinical aide-mémoires across a range of topics. Developed by Dr Kevin Fernando, Primary Care Hacks aim to provide a quick and easy resource for primary healthcare professionals and ultimately help improve patients' lives. •When to initiate GLP-1 RAs https://reference.medscape.com/cc3/p10/use-liraglutide-semaglutide-and-tirzepatide-adults-living-2024a1000kox?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Specialist prescribing criteria https://reference.medscape.com/cc3/p10/use-liraglutide-semaglutide-and-tirzepatide-adults-living-2024a1000kox?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1 •Tirzepatide dose escalation https://reference.medscape.com/cc3/p10/use-liraglutide-semaglutide-and-tirzepatide-adults-living-2024a1000kox?ecd=WNL_drugguide_251222_MSCPREF_primarycare_etid7968998&uac=148436CN&impID=7968998#1

domingo, 21 de diciembre de 2025

Editorial p869 The importance of partnerships The Lancet Psychiatry ++ +... +...

Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00296-2/abstract?utm_campaign=infocusalerts-psychiatry&utm_medium=email&dgcid=hubspot_email_infocusalerts-psychiatry_feature&_hsenc=p2ANqtz-_rRLNfaRrPjyg6uiF4ssN897l2A6bcEyN3PI51l6jGJ3k0yB_mp2ZHnnP3zxnbX1Sls_jo1BDzKFo3eUKjXRqCpsQnZQ&_hsmi=395420826&utm_content=395109541&utm_source=hs_email The effect of motivational interviewing on physical activity after hip fracture: a multisite, open-label, randomised controlled trial in Australia https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00089-3/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz--_q_qlaR2DNHAD5USgVUQgc8C9x8J2mQUHoBUUiuou2daIWoe6hCh5xhEIgmlSTaYwS0yMbCf_i9vS7cNS1P_BApWn3Q&_hsmi=395420826&utm_content=395109541&utm_source=hs_email Editorial p869 The importance of partnerships The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/issue/vol12no12/PIIS2215-0366(25)X0012-2 Editorial Communication and collaboration to reduce polypharmacy The Lancet Healthy Longevity https://www.thelancet.com/journals/lanhl/issue/vol6no10/PIIS2666-7568(25)X0011-8

Urgent need for infection prevention and control in prisons The Lancet Infectious Diseases + +... ++

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00732-7/fulltext?dgcid=raven_jbs_etoc_email Jan 2026 Volume 26Number 1p1-110, e1-e76 https://www.thelancet.com/journals/laninf/issue/vol26no1/PIIS1473-3099(25)X0013-X Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00311-1/abstract?dgcid=raven_jbs_etoc_feature_laninf Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00382-2/abstract?dgcid=raven_jbs_etoc_feature_laninf

FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection?utm_medium=email&utm_source=govdelivery

17th World Stroke Congress (WSC) 2025 +...

https://www.medscape.com/viewcollection/37911?ecd=WNL_conf_neuro_WSC-non-spon_251220_MSCPEDIT_etid7940706&uac=148436CN&impID=7940706

Editorial p987 Celebrating decades of progress in Lewy bodies research The Lancet Neurology ++ +... +...

Social isolation and access to cognitive disorder-related prespecialist care among older people: a 10-year nationwide cross-sectional study from the French National Alzheimer Database https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(25)00058-5/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-8W_0GNXL3yPwcZfdoODxJU5GgitrxoeTXnPoOfe2zoW5Q1kBq0BC3Kd11ekZTtFglRrjmAOec-E9OsjF6RrYv8snclSQ&_hsmi=395324206&utm_content=395110203&utm_source=hs_email Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00402-8/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-9S0gPvy-3PLF-guISRG8kOrJ8Kl9XsT9gYxW4W_tJgGXF8ylI5QkLJeCex_TQaLDIDXy2_tslSJFcN1qzLNp-H3RgWPA&_hsmi=395324206&utm_content=395110203&utm_source=hs_email Editorial p987 Celebrating decades of progress in Lewy bodies research The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol24no12/PIIS1474-4422(25)X0012-0 Editorial A sustainable primary care approach for obesity The Lancet Primary Care https://www.thelancet.com/journals/lanprc/issue/vol1no5/PIIS3050-5143(25)X0006-6

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? + +... +... +...

Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01776-3/abstract?dgcid=raven_jbs_etoc_feature_lancet 2025: an annus horribilis for health in the USA The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02588-7/fulltext?dgcid=raven_jbs_etoc_email Home Donna Wakefield, MBChB, MClinRes, FRCP Edin https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02467-5/abstract?dgcid=raven_jbs_etoc_feature_lancet Dec 20, 2025 Volume 406Number 10522p2865-2990 https://www.thelancet.com/journals/lancet/issue/vol406no10522/PIIS0140-6736(25)X0051-9

From pig to patient Pioneering transplants from pigs to humans could mark a turning point for organ replacement. +++++ +

https://www.drugdiscoverynews.com/from-pig-to-patient-16896 Biologic therapies push pharma to rethink inactive ingredients As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access. https://www.drugdiscoverynews.com/biologic-therapies-push-pharma-to-rethink-inactive-ingredients-16887 Targeting viral entry to expand antiviral drug discovery strategies New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development. https://www.drugdiscoverynews.com/targeting-viral-entry-to-expand-antiviral-drug-discovery-strategies-16902 AI helps radiologists find breast cancers earlier and faster Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency. https://www.drugdiscoverynews.com/ai-helps-radiologists-find-breast-cancers-earlier-and-faster-16830 Experimental treatments strike at a key mutation in deadly cancers Early clinical trials show that a KRAS G12D inhibitor can shrink tumors in patients with advanced pancreatic and other solid cancers. https://www.drugdiscoverynews.com/experimental-treatments-strike-at-a-key-mutation-in-deadly-cancers-16812?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--YBActFA955r8tUoZKZouHeFjmXLHb5BwxpprPI4YMd70hXHzeR0l67qcG7FOuzuPyklbAAv4OIuHsqM5oiaFKETVWSQ&_hsmi=395306581&utm_content=395306581&utm_source=hs_email Armoring up CAR T cells to fight solid tumors ArsenalBio equips T cells with multiple weapons to identify, attack, and persist against tumors, bringing the power of CAR T cell technology to solid cancers. https://www.drugdiscoverynews.com/armoring-up-car-t-cells-to-fight-solid-tumors-16276?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_6AyTJl4NEeeFiajbcBpwP7B4hlK3l5aj-reDn1YVsb9tJB3rXmQ1vsjsbFdoYIXu2isqaFdrC8nB9_Q3J4q4U9RfFDQ&_hsmi=395306581&utm_content=395306581&utm_source=hs_email

Weekly Rundown: Genentech partners with Caris Life Sciences in $1.1B deal Investments in solid tumor targets and autoimmune disease, success for a peanut allergy patch, a promising CAR T cell therapy for stiff person syndrome, and more led the news this week.

https://www.drugdiscoverynews.com/weekly-rundown-genentech-partners-with-caris-life-sciences-in-1-1b-deal-16903?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_0DDU_K4zwhLCr8udjJAPLr6cDvbUv1jDuLTP_Z95X1xcYdwJCkFpLpkxbsdSfJM7PKCXWAs7uYykSqyBdKTjr3qMk3A&_hsmi=395306581&utm_content=395306581&utm_source=hs_email

A day in the life: reconciling grief and gratitude 17 December 2025 Written by Amy Gietzen +++

https://rarerevolutionmagazine.com/a-day-in-the-life-reconciling-grief-and-gratitude/ Amy Gietzen invites us into her life with scleroderma, revealing the messy reality of a rare, chronic illness. She shares how she's learned that grief for her former self and gratitude for her present purpose can coexist, using her experience in advocacy to foster empathy in future healthcare students. Read this moving piece on resilience, the balancing act of daily life, and the strength found in carrying both grief and gratitude. Written by Amy Gietzen My journey with congenital erythropoietic porphyria (CEP) and the light I found through art 14 October 2025 https://rarerevolutionmagazine.com/my-journey-with-congenital-erythropoietic-porphyria-cep-and-the-light-i-found-through-art/ WHAT HAS BEEN YOUR STANDOUT MOMENT THIS YEAR? “The launch of our new title, RARE Revolution insider®. I am immensely proud of what the team has created with this new membership content. From content curation and writing quality to layout. It further cements our mission to ensure we are doing all we can to elevate rare disease as a priority topic of conversation.” https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=61553d05-0d27-4f70-9db3-615793924b92&pnum=12 WHAT HAS BEEN YOUR STANDOUT MOMENT THIS YEAR? “Two, please, if I may? The standouts for me have been seeing the reach and impact of our work this year. Our incredible analytics only tell us part of the picture. What really stands out is every email of feedback that the team and I receive as a result of our digital and magazine content. Our impact doesn’t end with readers and metrics—it starts there. It’s the onward connections, collaborations and access to support that spring from each of our articles that truly mean the most to us. Of course, I can’t end 2025 without mentioning the launch of our new RARE Revolution insider® title and Cognito AI librarian tool. Not only am I incredibly proud of the innovation that this launch represents and the hard work and ingenuity of the whole team and external partners, but also of the immensely high-quality content we are delivering. I am excited to see what 2026 brings for our new fledgling.”

Assessing Conditioning Regimens for HSCT: Optimizing Patient Outcomes Authors: Mohamad Mohty, MD, PhD; Daniele Avenoso, MD, PhD; Simona Sica, MD, PhD; Sergio Giralt, MD, FACP, FASTCT

https://www.medscape.org/viewarticle/1003061_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251219-1003061-ES_LANG-HONC

Raising the Bar on Breast Cancer Screening and Management Authors: Stamatia V. Destounis, MD, FACR, FSBI, FAIUM; Heather I. Greenwood, MD; Linda Moy, MD; Sarah Eskreis-Winkler, MD, PhD

https://www.medscape.org/viewarticle/raising-bar-breast-cancer-screening-and-management-2025a1000jjj?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251221-OUS-HONC-raising-bar-breast-cancer-screening-and-management-2025a1000jjj-cta

NF1-Associated Plexiform Neurofibromas in Adults: Which Patients Could Benefit From Emerging Systemic Therapies? Authors: Andrea Gross, MD; João Passos, MD

https://www.medscape.org/viewarticle/1003044?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251220-OUS-HONC-1003044-cta

Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer: Translating Science Into Clinical Practice Authors: Rahul Gosain, MD, MBA; Rohit Gosain, MD; David S. Hong, MD; Theodore W. Laetsch, MD; Jarushka Naidoo, MB, BCH, MHS

https://www.medscape.org/viewarticle/1002679?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251220-OUS-HONC-1002679-cta

Hormone Receptor-Positive Metastatic Breast Cancer: Novel Endocrine-Based Strategies and Options After Progression Authors: Volkmar Müller, MD; Erica L. Mayer, MD, MPH

https://www.medscape.org/viewarticle/1002835?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251220-OUS-HONC-1002835-cta

Aging With T1D: Success Story Brings Challenges | Changes in Driving Patterns May Signal MCI ++++ ++++

Which cancers show the strongest risk reduction with plant-based dietary patterns (Medscape AI) +... +++++ +++++ ++ +++

sábado, 20 de diciembre de 2025

Estrogen drives gut pain and explains higher rates of IBS in women

https://www.news-medical.net/news/20251218/Estrogen-drives-gut-pain-and-explains-higher-rates-of-IBS-in-women.aspx

HPV vaccination reduces risk of vulvar and vaginal lesions

https://www.news-medical.net/news/20251218/HPV-vaccination-reduces-risk-of-vulvar-and-vaginal-lesions.aspx

Whooping cough cases rise sharply across the United States

https://www.news-medical.net/news/20251218/Whooping-cough-cases-rise-sharply-across-the-United-States.aspx

Roadmap for Engaging the Public as Partners in Clinical Research

https://www.nih.gov/about-nih/nih-director/statements/roadmap-engaging-public-partners-clinical-research ROADMAP FOR ENGAGING THE PUBLIC AS PARTNERS IN CLINICAL RESEARCH https://osp.od.nih.gov/wp-content/uploads/2025/12/NExTRACs-ENGAGE-Report_FINAL.pdf At the National Institutes of Health (NIH), engendering trust and confidence in the research we support is one of our top priorities. Three things guide these efforts: engaging in open, honest dialogue, acting in transparency, and delivering on our commitment to advancing science and improving health. To help guide this work, the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) recently undertook a multi-year effort to provide the NIH with a roadmap for incorporating public voices in clinical research (see NExTRAC report) . Deliberations were informed by a team of multi-disciplinary experts and community conversations across the country , specifically asked to think about strategies for incorporating public voices at every stage of the clinical research process. https://partnersinresearch.nih.gov/members/ I am pleased to endorse these recommendations, which focus on: --providing a clear vision and framework for maximally involving patients and communities in clinical research; --ensuring that people and communities have meaningful input into the agenda and direction of research that is relevant and impactful for them; and --increasing transparency for how research participant data are utilized in moving the scientific enterprise forward. NIH is eager to begin implementing this roadmap, starting in 2026. First, NIH will work with the community to make the return of participant research results standard practice. Initial efforts will focus on returning summary-level research results, with the intent of augmenting practices that result in returning individual-level research results to research participants. Providing individuals with their research data so they can make their own healthcare decisions is one of my top priorities as NIH Director. NIH is also working towards harnessing the widespread adoption of electronic health records and other large scale electronic clinical information systems to accelerate biomedical research in ways not previously possible. In the spirit of transparency, NIH is establishing agency-wide principles to foster, promote, and guide the responsible conduct of research using clinical data. These principles serve as an initial transparent foundation for building trust with the public in how their data are respected and shared to drive improvements in health across the country. I want to thank the NExTRAC and the ENGAGE Working Group members for their keen insights and thoughtful deliberations. Their efforts will serve as a valuable tool toward improving the health of all Americans. Dr. Jay Bhattacharya NIH Director About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit . NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This Statement is available online at:

Studies on nano magnesium oxide modified acrylic resin in antibacterial coating application Tirthankar Jana* [1] , Tapan Kumar Dhar [1]

https://www.academia.edu/2997-2027/2/4/10.20935/AcadMatSci8044 The present study is related to the impact of nano magnesium oxide modified hybrid acrylic resin as a dual functional component in coating applications. Such nano magnesium oxide modified hybrid acrylic acts as a film former as well as antimicrobial agent. Nano magnesium oxide modification into acrylic resin was carried out through chemical modification with specially designed acrylic resin and confirmed by IR spectroscopic and SEM analysis. The effect of nano magnesium oxide modified hybrid acrylic resin was evaluated in water-based paint composition and compared against acrylic paint containing commercial biocides. The results revealed enhancement of coating properties like opacity (5%), whiteness (6%), gloss (7.5%) and antibacterial performance (more than 99% reduction of bacterial concentration) in magnesium oxide modified acrylic paint against unmodified ones and comparable with paint properties containing commercial biocides. The study shows that specially designed nano MgO modified acrylic resin can be used to make antibacterial coating without using commercial biocides.

Patients’ Insights Illuminated: A Rapid-Fire Dive Into CLL and MCL Authors: Lorna Warwick; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD; Nicole Lamanna, MD; David Ball; Vivienne Ball

https://www.medscape.org/viewarticle/1002737?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251219-OUS-HONC-1002737-cta

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers Authors: Elizabeth Smyth, MD; Samuel J. Klempner, MD, FASCO, Eric Van Cutsem, MD, PhD

https://www.medscape.org/viewarticle/1002919?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_416293.16_ace_launch

Editorial p1 Diabetes and cancer in the age of multimorbidity The Lancet Diabetes & Endocrinology +++ +...

Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00288-8/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-8oahYvG7-CTIpexG2ufMYg9LmcjPbh_mwLweZG_RpaEP-d27IncgR96wwCaRbbLpxJ_r_LeD14yaG0wRzYb6Oo7mzrlQ&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00285-2/fulltext?dgcid=hubspot_update_feature_updatealerts_landia&utm_campaign=update-landia&utm_medium=email&_hsenc=p2ANqtz--AqoYIv0zQvdHrMjQMR6McVJQwTmZHyWrb2QZI0S02GJsgMLX0geOytTrSeHFEQlLbowHeMdNkBypPnJUpjVp4RHMbFw&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00265-7/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-9KJPrux5d3_Kw96kWlaJ4pJyaqnpDQs9wPeXVKGsPZ16U2_jv6jBgw56s0N7_r28rH-_7nLNjewVV2RVo-0R_SIu2IoA&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Editorial p1 Diabetes and cancer in the age of multimorbidity The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no1/PIIS2213-8587(25)X0013-9

Editorial p1 Turning policy into action for brain health The Lancet Neurology +++ +...

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext?dgcid=hubspot_update_feature_updatealerts_laneur&utm_campaign=update-laneur&utm_medium=email&_hsenc=p2ANqtz--C4hczGmVdXlcmcdW6Yg16xrTGqF5t1vXghIfIZjUmUv-kPI3oMMj3UpCyklcM8Ks4zaUXkb0_n7nBO3BbVwNONu1s3A&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO2MSE): a prospective, multicentre case–control study https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00379-5/fulltext?dgcid=hubspot_update_feature_updatealerts_laneur&utm_campaign=update-laneur&utm_medium=email&_hsenc=p2ANqtz--2Qir_Kag4S30b-jCQR2M0StqZeVbpMlz-qvSkO7yaQ8UrGiY4LMXqOKihPXhT9SSFmX07WXmOa_dBOElo_qZi29teCQ&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00356-4/abstract?utm_campaign=update-laneur&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laneur&_hsenc=p2ANqtz-9Ww4b67TfrrvF8J_V-wrRbrONovM7RIrF4z9HLLSmiceMGFAt0RUsKGxw1RJZ80lwemCM30GLTWsB4wVvtddVKtB2-HQ&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Editorial p1 Turning policy into action for brain health The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol25no1/PIIS1474-4422(25)X0013-2

Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_251219

Cutting carbs, not fat, may better control appetite in women +++++

Cutting carbs, not fat, may better control appetite in women https://www.news-medical.net/news/20251219/Cutting-carbs-not-fat-may-better-control-appetite-in-women.aspx A short-term clinical trial suggests that cutting carbohydrates, not fat, may be better for curbing food cues and emotional eating in women living with lipedema. Purple Power: Evidence-Based Health Benefits of Anthocyanin-Rich Diets https://www.news-medical.net/health/Purple-Power-Evidence-Based-Health-Benefits-of-Anthocyanin-Rich-Diets.aspx Purple foods aren’t just pretty! Here’s what anthocyanins are actually doing inside your body, and why the best evidence points to specific heart and brain benefits (with skin protection emerging). Chrononutrition Explained: Why When You Eat Matters for Metabolic Health https://www.news-medical.net/health/Chrononutrition-Explained-Why-When-You-Eat-Matters-for-Metabolic-Health.aspx Late-night meals can quietly derail glucose control and cardiovascular health. Here’s what chrononutrition research and clinical evidence suggest you should eat, avoid, and shift earlier to protect metabolic function. How Artificial Food Coloring Affects Children's Behavior and Health https://www.news-medical.net/health/How-Artificial-Food-Coloring-Affects-Children-Behavior-and-Health.aspx Synthetic food dyes are widely used in packaged foods and can disproportionately affect children due to higher relative intake and developmental vulnerability. Evidence from clinical trials, animal studies, and regulatory reviews links certain dyes to behavioral changes, allergic reactions, and emerging concerns involving the gut–brain axis. Early peanut introduction can prevent allergy but parents need clearer guidance https://www.news-medical.net/news/20251218/Early-peanut-introduction-can-prevent-allergy-but-parents-need-clearer-guidance.aspx

Analytical Results of Testing Food for PFAS from Environmental Contamination

https://www.fda.gov/food/environmental-contaminants-food/analytical-results-testing-food-pfas-environmental-contamination?utm_medium=email&utm_source=govdelivery FDA Releases Additional 2024 PFAS Results Results for Six Additional TDS Regional Collections Added to Database View on the FDA Website December 19, 2025 Constituent Update Today, the FDA is sharing per- and polyfluoroalkyl substances (PFAS) results for six additional Total Diet Study (TDS) regional collections collected in 2024, adding to the eight TDS collections already posted on the Analytical Results of Testing Food for PFAS from Environmental Contamination webpage. The goal of this ongoing sampling is to better understand background contamination levels, U.S. consumers’ average exposure to PFAS from foods, prioritize foods for future monitoring, and guide further FDA activities. A summary of PFAS results for these six additional TDS collections are as follows: 503 of 542 (92.8%) samples had no detections 39 of 542 (7.2%) samples had trace detections of one or more PFAS analytes: cod, shrimp, clams, salmon, tilapia, catfish pepperoni, beef steak, ground beef, chicken breast half & half, whole milk, skim milk kale 4 of 39 samples had non-trace detections of one or more PFAS analytes: shrimp, clams catfish, tilapia To estimate dietary exposure to PFAS from the general food supply, the FDA has been testing fresh and processed foods for certain PFAS since 2019. Results for PFAS testing of TDS samples began for the first time in 2019. It is important to note that to date no PFAS have been detected in 95% (1,290 out of 1,352) of the fresh and processed foods tested from the TDS. TDS data can show how much contamination is present and help estimate possible exposure, but they should not be used on their own to decide whether something is safe or harmful to health. In the past six years, the FDA has made significant progress in understanding PFAS and is leading the science in developing validated methods for testing for PFAS in increasingly diverse types of foods. Based on our validated methods, FDA currently tests for up to 30 PFAS in various foods, including bread and grains; fruits and vegetables; meat, eggs, and dairy products, including milk; and seafood. To date, the FDA has tested over 1,900 samples of food for PFAS through TDS and targeted assignments and surveys. The FDA will continue to pursue additional sampling to better understand PFAS in the U.S. food supply. Changes to the PFAS Website First, to improve transparency and provide greater context about our analytical findings, we have updated our reporting to include both Method Detection Limits (MDL) and Limits of Quantification (LOQ), rather than relying solely on MDL values. Results are now categorized as follows: Below MDL: Not detected Above MDL but below LOQ: Trace levels reported in italics Above LOQ: Quantifiable levels reported Second, we are now including an additional toxicological reference value for assessing the safety of perfluorodecanoic acid (PFDA) levels found in food. Future PFAS Testing The FDA will continue to analyze TDS samples for PFAS with the goal of estimating U.S. consumers’ dietary PFAS exposure to help inform FDA’s activities to reduce PFAS levels in food. Testing will analyze a wide array of foods through TDS, including bread and grains; fruits and vegetables; meat, eggs, and dairy products, including milk; and seafood. The FDA will continue to work closely with our federal partners and state departments of agriculture and health to share information and enhance collaboration in our efforts to gather a more robust dataset of PFAS in foods as we work together to reduce the public’s dietary exposure to PFAS.